The effect of melatonin implants during the seasonal anestrus on embryo production after superovulation in aged high-prolificacy Rasa Aragonesa ewes.
Forcada. F F; Abecia. J A JA; Cebrián-Pérez. J A JA; Muiño-Blanco. T T; Valares. J A JA; Palacín. I I; Casao. A A
Key Findings
- Melatonin raised ovarian cyclicity only in one specific recovery period (year 2, recovery 2).
- Embryo viability improved with melatonin: more blastocysts, higher viability and better freezability in that same period.
- Melatonin reduced the number and proportion of non‑viable (degenerate) embryos.
Practical Outcomes
- For biohackers, the study hints that melatonin might enhance egg/embryo quality in older females, but the data are from sheep and specific timing (March implants). It’s not a ready‑to‑use protocol for humans, though it supports the idea of melatonin supplementation for reproductive health, pending human trials.
Summary
In older, high‑producing sheep, giving melatonin implants in March modestly improved the quality and survival of embryos after hormone‑driven superovulation, especially three months later, but it didn’t consistently boost ovulation itself.
Abstract
The aim of this study was to assess the effect of melatonin implants administered in March on the ovarian cyclicity, ovulatory response and embryo production after repeated superovulation of selected high-prolificacy Rasa Aragonesa aged ewes. During the seasonal anestrus of two consecutive years, 113 superovulatory treatments have been performed. Ewes were treated (M) or not (C) with melatonin implants in March (day 0). All of them received intravaginal progestogen sponges on day 24 (recovery 1) and 80 (recovery 2) after melatonin implants insertion in year 1, and on day 28 and 77 in year 2. The intravaginal sponges were removed after 14 days. Superovulatory treatments consisted of eight doses in decreasing concentrations (2 mL x 2 and 1 mL x 6) of oFSH (Ovagen) administered twice daily starting 72 h before sponge removal. Seven days after the onset of estrus, embryos were recovered by laparotomy. Melatonin increased cyclicity only in recovery 2 year 2 (83% versus 42%; P < 0.05) but not in the other experimental periods. Among the 78% (88) ewes that ovulated and produced functional corpora lutea, melatonin implants tended to improve embryo viability in recovery 2 by increasing the number of blastocysts per superovulatory treatment (2.4 +/- 0.6 versus 1.1 +/- 0.4; P = 0.09), the rate of viability (67 +/- 9% versus 43 +/- 9%; P < 0.05), and freezability (55 +/- 9% versus 33 +/- 8%; P < 0.05). More specifically, melatonin induced a significant reduction of the number and rate of non-viable (degenerate and retarded) embryos in recovery 2 (0.4+/-0.1 embryos versus 1.3 +/- 0.3 embryos and 4 +/- 1% versus 22 +/- 6%, respectively; P < 0.05). Our results demonstrate that melatonin implants in March can improve at medium term (3 months after implantation) the viability of embryos collected from selected high-prolificacy Rasa Aragonesa aged ewes after superovulation.
Study Information
pubmed
2005
2005-06-20T00:00:00.000Z
10.1016/j.theriogenology.2005.05.038